Eli Lilly Will File For Retatrutide Approval—As Study Shows Average Weight Loss Of 56 Pounds

Analysts flagged retatrutide as a potential blockbuster weight-loss drug pending approval, citing upside to $3.8B sales by 2030 (TD Cowen) and $15.6B by 2031 (GlobalData). These forecasts suggest strong demand expectations but are contingent on regulatory approval and eventual launch execution.

Analysis

Analysts flagged retatrutide as a potential blockbuster weight-loss drug pending approval, citing upside to $3.8B sales by 2030 (TD Cowen) and $15.6B by 2031 (GlobalData). These forecasts suggest strong demand expectations but are contingent on regulatory approval and eventual launch execution.